Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic–pituitary–adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: Preliminary results

References

• Aguilera G. Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal. J Ster Biochem Mol Biol 1993; 45: 147–151
   PubMed Web of Science ®Google Scholar
• Aguilera G, Young WS, Kiss A, Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology 1995; 61: 437–444
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes-2006. Diab Care 2006; 29: S4–S42
   PubMed Web of Science ®Google Scholar
• Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. JCEM 2002; 87: 5587–5593
   PubMed Web of Science ®Google Scholar
• Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terron JA, Falcon-Neri A, Ito T, Juorio AV, Saavedra JM. Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic–pituitary–adrenal response to isolation stress. Endocrinology 2001; 142: 3880–3889
   PubMed Web of Science ®Google Scholar
• Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotrophin-releasing factor response to isolation stress. Brain Res 2007; 20(1142)92–99, Epub 2007 January 19
   Web of Science ®Google Scholar
• Bohlender J, Franke S, Sommer M, Stein G. Advanced glycation end products: A possible link to angiotensin in an animal model. Ann NY Acad Sci 2005; 1043: 681–684
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Chrousos GP. Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: Neural and immune inputs. JCEM 1999; 84: 1729–1736
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Webster EL, Torpy DJ, Richman SJ, Mitsiades N, Igel M, Lewis DB, Rice KC, Joost HG, Tsokos M, Chrousos GP. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary–adrenal function, body weight, and metabolic regulation. Endocrinology 1998; 139: 1546–1555
   PubMed Web of Science ®Google Scholar
• Bregonzio C, Armando I, Ando H, Jecova M, Baiardi G, Saavedra JM. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Psysiol Gastrointest Liver Physiol 2003; 285: 414–423
   PubMed Web of Science ®Google Scholar
• Broadley AJ, Korszum A, Abdelaal E, Moskvina V, Jones CJ, Nash GB, Ray C, Deanfield J, Frenneaux MP. Inhibition of cortisol production with metyrapone prevents mental stress-induced endothelial dysfunction and baroreflex impairment. JACC 2005; 19: 344–350
   Web of Science ®Google Scholar
• Broadley AJ, Korszum A, Abdelaal E, Moskvina V, Deanfield J, Jones CJ, Frenneaux MP. Metyrapone improves endothelial dysfunction in patients with treated depression. JACC 2006; 48: 170–175
   Web of Science ®Google Scholar
• Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 2005; 46: 533–539, Epub 2005 August 22
   PubMed Web of Science ®Google Scholar
• Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Ann Rev Physiol 2005; 67: 259–284
   PubMed Web of Science ®Google Scholar
• Coiro V, Volpi R, Capretti L, Caffarri G, Colla R, Giuliani N, Chiodera P. Stimulation of ACTH and GH release by angiotensin II in normal men is mediated by the AT1 receptor subtype. Regul Pept 1998; 74: 27–30
   PubMedGoogle Scholar
• Contoreggi C, Rice KC, Chrousos G. Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders. Neuroendocrinology 2004; 80: 111–123
   PubMed Web of Science ®Google Scholar
• Cooper J. The leyton obsessional inventory. Psychol Med 1970; 1: 48–64
   PubMedGoogle Scholar
• Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. JACC 2002; 39: 257–265
   Web of Science ®Google Scholar
• Deicken RF. Captopril treatment of depression. Biol Psychiat 1986; 21: 1425–1428
   PubMed Web of Science ®Google Scholar
• Derogatis LR. SCL-90-R administration, scoring and procedures manualIInd ed. Procedures psychometric research. 1983, Baltimore, MD
   Google Scholar
• Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong WF. Analysis by immunocytochemistry and in situ hybridization of renin and its mRNA in kidney, testis, adrenal and pituitary of the rat. Proc Natl Acad Sci USA 1986; 83: 7552–7556
   PubMed Web of Science ®Google Scholar
• Dessi-Fulgheri P, Alagna S, Madeddu P, Glorioso N, Masala A, Rovasio PP, Leoni C, Rappelli A. Blunted adrenocorticotrophic hormone release during captopril treatment. J Hypert (Supplement) 1985; 3: 125–127
   Web of Science ®Google Scholar
• Du XJ, Cox HS, Dart AM, Esler MD. Depression of efferent parasympathetic control of heart rate in rats with myocardial infraction: Effect of losartan. J Cardiovasc Pharmacol 1998; 31: 937–944
   PubMed Web of Science ®Google Scholar
• Ehrhart-Bornstein M, Bornstein SR, Gonzalez-Hernandez J, Holst JJ, Waterman MR, Scherbaum WA. Sympathoadrenal regulation of adrenocortical steroidogenesis. Endocr Res 1995; 21: 13–24
   PubMed Web of Science ®Google Scholar
• Gaillard RC, Grossman A, Gillies G, Rees LH, Besser GM. Angiotensin II stimulates the release of ACTH from dispersed rat anterior pituitary cells. Clin Endocrinol (Oxf) 1981; 15: 573–578
   PubMed Web of Science ®Google Scholar
• Ganong WF. Blood, pituitary and brain renin–angiotensin systems and regulation of secretion of anterior pituitary gland. Front Neuroendocrinol 1993; 14: 233–249
   PubMed Web of Science ®Google Scholar
• Germain L, Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiat 1988; 25: 489–493
   Web of Science ®Google Scholar
• Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin–angiotensin–aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metabol 2005; 16: 120–126
   PubMed Web of Science ®Google Scholar
• Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982; 299: 355–357
   PubMed Web of Science ®Google Scholar
• Gohlke P, Kox T, Jurgensen T, von Kugelgen S, Rascher W, Unger T, Culman J. Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 477–483
   PubMed Web of Science ®Google Scholar
• Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metabol Clin North Amer 2001; 30: 695–728
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio heart study. Diab Care 2002; 25: 1177–1184
   PubMed Web of Science ®Google Scholar
• Hauger RL, Aguilera G, Baukal AJ, Catt KJ. Characterization of angiotensin II receptors in the anterior pituitary gland. Mol Cell Endocrinol 1982; 25: 203–212
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Jacob S, Kinnick RT, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese zucker rats. Hypertension 2001; 38: 884–890
   PubMed Web of Science ®Google Scholar
• Jain P, Armando I, Juorio AV, Barden N, Benicky J, Saavedra JM. Decreased hypothalamic and adrenal angiotensin II receptor expression and adrenomedullary catecholamines in transgenic mice with impaired glucocorticoid receptor function. Neuroendocrinology 2004; 80: 171–180
   PubMed Web of Science ®Google Scholar
• Jezova M, Armando I, Bregonzio C, Yu ZX, Qian S, Ferrans VJ, Imboden H, Saavedra JM. Angiotensin II AT (1) and AT (2) receptors contribute to maintain basal adrenomedullary norepinephrine synthesis and tyrosine hydroxylase transcription. Endocrinology 2003; 144: 2092–2101
   PubMed Web of Science ®Google Scholar
• Kalogeras KT, Calogero AE, Kuribayiashi T, Khan I, Gallucci WT, Kling MA, Chrousos GP, Gold PW. In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic–pituitary–adrenal function: Pharmacological and clinical implications. JCEM 1990; 70: 1462–1471
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi S, Mather K, Baron A, Follman D, Sullivan G, Quon M. Quantitive insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. JCEM 2000; 85: 2402–2410
   PubMed Web of Science ®Google Scholar
• Kersaw EE, Flier JS. Adipose tissue as an endocrine organ. JCEM 2004; 89: 2548–2556
   PubMed Web of Science ®Google Scholar
• Landas S, Phillips MI, Stamler JF, Raizada MK. Visualization of specific angiotensin II binding sites in the brain by fluorescent microscopy. Science 1980; 14: 791–793
   Web of Science ®Google Scholar
• Latchford KJ, Ferguson AV. Angiotensin depolarizes parvocellular neurons in paraventricular nucleus through modulation of putative nonselective cationic and potassium conductances. Am J Physiol Reg Integr Comp Physiol 2005; 289: R52–R58
   PubMed Web of Science ®Google Scholar
• Lavoie JL, Sigmund CD. Minireview: Overview of the renin–angiotensin system—an endocrine and paracrine system. Endocrinology 2003; 144: 2179–2183
   PubMed Web of Science ®Google Scholar
• Lenkei Z, Corvol P, Llorens-Cortes C. Comparative expression of vasopressin and angiotensin type-1 receptor mRNA in rat hypothalamic nuclei: A double in situ hybridization study. Brain Res Mol Brain Res 1995; 34: 135–142
   PubMedGoogle Scholar
• Lenkei Z, Nuyt AM, Grouselle D, Corvol P, Llorens-Cortes C. Identification of endocrine cell populations expressing the AT1B subtype of angiotensin II receptors in the anterior pituitary. Endocrinology 1999; 140: 472–477
   PubMed Web of Science ®Google Scholar
• Liu JH, Muse K, Contreras P, Gibbs D, Vale W, Rivier J, Yen SS. Augmentation of ACTH-releasing activity of synthetic corticotropin releasing factor (CRF) by vasopressin in women. JCEM 1983; 57: 1087–1089
   PubMed Web of Science ®Google Scholar
• Livett BG, Marley PD. Noncholinergic control of adrenal catecholamine secretion. J Anat 1993; 183: 277–289
   PubMed Web of Science ®Google Scholar
• Livett BG, Marley PD, Wan DC, Zhou XF. Peptide regulation of adrenal medullary function. J Neural Transm (Supplementum) 1990; 29: 77–89
   PubMedGoogle Scholar
• Makino S, Hashimoto K, Gold PW. Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol Biochem Behav 2002; 73: 147–158
   PubMed Web of Science ®Google Scholar
• Mangos GJ, Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000; 13: 1155–1160
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-coverting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003; 91: 30H–37H
   PubMed Web of Science ®Google Scholar
• Michelson D, Galliven E, Hill L, Demitrack M, Chrousos G, Gold P. Chronic imipramine is associated with diminished hypothalamic–pituitary–adrenal axis responsivity in healthy humans. JCEM 1997; 82: 2601–2606
   PubMed Web of Science ®Google Scholar
• Mottola CA. Measurement strategies: The visual analogue scale. Decubitus 1993; 6: 56–58
   PubMedGoogle Scholar
• Murakami K, Ganong WF. Site at which angiotensin II acts to stimulate ACTH secretion in vivo. Neuroendocrinol 1987; 46: 231–235
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Ito T, Hoe K, Saavedra JM. Chronic peripheral administration of the angiotensin II AT (1) receptor antagonist candesartan blocks brain AT (1) receptors. Brain Res 2000; 871: 29–38
   PubMed Web of Science ®Google Scholar
• Okuyama S, Sakagawa T, Chaki S, Imagawa Y, Ichiki T, Inagami T. Anxiety-like behaviour in mice lacking the angiotensin II type-2 receptor. Brain Res 1999; 821: 150–159
   PubMed Web of Science ®Google Scholar
• Pawlikowski M. Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas. Folia Histochem Cytobiol 2006; 44: 173–177
   PubMed Web of Science ®Google Scholar
• Phillips MI. Functions of angiotensin in the central nervous system. Ann Rev Physiol 1987; 49: 413–435
   PubMed Web of Science ®Google Scholar
• Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept 1998; 78: 1–11
   PubMedGoogle Scholar
• Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin–angiotensin systems. Regul Pept 1993; 22: 1–20
   Google Scholar
• Pilowski I. Dimensions of hypochondriasis. Br J Psych 1967; 113: 89–93
   PubMed Web of Science ®Google Scholar
• Plunkett LM, Correa FM, Saavedra JM. Quantitative autoradiographic determination of angiotensin-converting enzyme binding in rat pituitary and adrenal glands with 125I-351A, a specific inhibitor. Regul Pept 1985; 28: 263–272
   Google Scholar
• Protogerou AD, Blacher J, Aslangul E, Le Jeunne C, Lekakis J, Mavrikakis M, Safar ME. Gender influence on metabolic syndrome's effects on arterial stiffness and pressure wave reflections in treated hypertensive subjects. Atherosclerosis 2006; 23, Epub ahead of print
   Google Scholar
• Rabano M, Pena A, Brizuela L, Macarulla JM, Gomez-Munoz A, Trueba M. Angiotensin II-stimulated cortisol secretion is mediated by phospholipase D. Mol Cell Endocrinol 2004; 222: 9–20
   PubMed Web of Science ®Google Scholar
• Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763–E778
   PubMed Web of Science ®Google Scholar
• Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R, Paiardi S, Bianchi R, Rugeri G, Boari GE, Muiesan ML, Salvetti M, Zani F, Miclini M, Rosei EA. Effect of treatment with candesartan or enapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005; 45: 659–665
   PubMed Web of Science ®Google Scholar
• Rogers KM, Bonar CA, Estrella JL, Yang S. Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am J Physiol Heart Circul Physiol 2002; 283: H1922–H1928
   PubMed Web of Science ®Google Scholar
• Roy MS, Roy A, Gallucci WT, Collier B, Young K, Kamilaris TC, Chrousos GP. The ovine corticotropin-releasing hormone-stimulation test in type I diabetic patients and controls: Suggestion of mild chronic hypercortisolism. Metabolism 1993; 42: 696–700
   PubMed Web of Science ®Google Scholar
• Saavedra JM. Brain and pituitary angiotensin. Endocr Rev 1992; 13: 329–380
   PubMed Web of Science ®Google Scholar
• Saavedra JM, Pavel J. Angiotensin II AT1 receptor antagonists inhibit the angiotensin–CRF–AVP axis and are potentially useful for the treatment of stress-related and mood disorders. Drug Devel Res 2005; 65: 237–269
   Web of Science ®Google Scholar
• Saavedra JM, Armando I, Bregonzio C, Juorio A, Macova M, Pavel J, Sanchez-Lemus E. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 2005; 31: 1123–1134
   Web of Science ®Google Scholar
• Saini AK, Patel RJ, Sharma SS, H SAK. Edaravone attenuates hydroxyl radical stress and augmented angiotensin II response in diabetic rats. Pharmacol Res 2006; 54: 6–10, Epub 2006 march 20
   PubMed Web of Science ®Google Scholar
• Sander-Jensen K, Secher NH, Astrup A, Christensen NJ, Damkjaer-Nielsen M, Giese J, Warberg J, Bie P. Angiotensin II attenuates reflex decrease in heart rate and sympathetic activity in man. Clin Physiol 1988; 8: 31–40
   PubMedGoogle Scholar
• Sasamura H, Ktamura Y, Nakamura M, Ryuzaki M, Saruta T. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellurar matrix metabolism in patient with essential hypertension. Clin Exp Hypert 2006; 28: 511–520
   PubMed Web of Science ®Google Scholar
• Seltzer A, Bregonzio C, Armando I, Baiardi G, Saavedra JM. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res 2004; 28: 9–18
   Web of Science ®Google Scholar
• Shinozaki K, Kazuhide A, Yoshihiko N, Takeshi S, Atsunori K, Tomio O. Evidence for causal role of the renin–angiotensin system in vascular dysfuction associated with insulin resistance. Hypertension 2004; 43: 255–262
   PubMed Web of Science ®Google Scholar
• Spielberger CD, Gorsuch RL, Lushene RE. Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto, CA 1970, 53
   Google Scholar
• Spinedi E, Negro-Vilar A. Angiotensin II and ACTH release: Site of action and potency relative to corticotropin releasing factor and vasopressin. Neuroendocrinol 1983; 37: 446–453
   PubMed Web of Science ®Google Scholar
• Spinedi E, Rodriguez G. Angiotensin II and adrenocorticotropin release: Mediation by endogenous corticotropin-releasing factor. Endocrinology 1986; 119: 1397–1402
   PubMed Web of Science ®Google Scholar
• Spoelstra-de Man AM, van Ittersum FJ, Schram MT, Kamp O, van Dijk RA, Ijzerman RG, Twisk JW, Brouwer CB, Stehouwer CD. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. J Hum Hypert 2006; 20: 599–611
   PubMed Web of Science ®Google Scholar
• Thomas J, Jones G, Scarinci I, Brantley P. A descriptive and comparative study of the prevalence of depressive and anxiety disorders in low-income adults with type 2 diabetes and other chronic illnesses. Diab Care 2003; 26: 2311–2317
   PubMed Web of Science ®Google Scholar
• Tsigos C, Chrousos GP. Physiology of the hypothalamic–pituitary–adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metabol Clin North Am 1994; 23: 451–466
   PubMed Web of Science ®Google Scholar
• Tsigos C, Chrousos GP. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002; 53: 865–871
   PubMed Web of Science ®Google Scholar
• Tsigos C, Young RJ, White A. Diabetic neuropathy is associated with increased activity of the hypothalamic–pituitary–adrenal axis. JCEM 1993; 76: 554–558
   PubMed Web of Science ®Google Scholar
• Tsutsumi K, Saavedra JM. Angiotensin-II receptor subtypes in median eminence and basal forebrain areas involved in regulation of pituitary function. Endocrinology 1991A; 129: 3001–3008
   PubMed Web of Science ®Google Scholar
• Tsutsumi K, Saavedra JM. Characterization of AT2 angiotensin II receptors in rat anterior cerebral arteries. Am J Physiol 1991B; 261: 667–670
   PubMed Web of Science ®Google Scholar
• Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991C; 261: 209–216
   PubMed Web of Science ®Google Scholar
• Uresin Y, Erbas B, Ozek M, Ozkok E, Gurol AO. Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. J Renin Angiotensin Aldosterone Syst 2004; 5: 93–96
   PubMed Web of Science ®Google Scholar
• Veltmar A, Culman J, Qadri F, Rascher W, Unger T. Involvement of adrenergic and angiotensinergic receptors in the paraventricular nucleus in the angiotensin II-induced vasopressin release. J Pharmacol Exp Therap 1992; 263: 1253–1260
   PubMed Web of Science ®Google Scholar
• Volpi R, Chiodera P, Capretti L, Caiazza A, Caffarri G, Magoti MG, Boni S, Coiro V. Inhibition by somatostatin of the growth hormone, but not corticotrophin response to angiotensin II in normal men. Horm Res 1996; 45: 269–272
   PubMedGoogle Scholar
• Wassmann K, Ghiassi A, Wassmann S, Bohm M, Nickening G. AT1 receptor antagonism improves endothelial dysfunction in postmenopausal women. Maturitas 2006; 20: 176–183
   Web of Science ®Google Scholar
• Wells KB, Golding JM, Burnam MA. Affective, substance use, and anxiety disorders in persons with arthritis, diabetes, heart disease, high blood pressure, or chronic lung conditions. Gen Hosp Psych 1989; 11: 320–327
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Elmfeldt D. Findings and implications of the study of cognition and prognosis in the elderly (SCOPE)—a review. Blood Press 2006; 15: 71–79
   PubMed Web of Science ®Google Scholar
• Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiat 1984; 141: 110–111
   PubMed Web of Science ®Google Scholar
• Zung WWK. A self-rating depression scale. Arch Gen Psychiat 1965; 12: 63–70
   PubMed Web of Science ®Google Scholar